What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia?

Current Psychiatry Reports

Volumn 14, Issue 5, 2012, Pages 494-502

  McCall, Catherine ^b   McCall, W Vaughn ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Comorbid insomnia; Hypnotics; Insomnia; Off label; Psychiatry; Sleep disorders; Slow wave sleep; SWS

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DOXEPIN; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; LORAZEPAM; MELATONIN; METHADONE; MIRTAZAPINE; NABILONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PLACEBO; PREGABALIN; QUETIAPINE; TIAGABINE; TRAZODONE; TRAZODONE CONTRAMID; UNCLASSIFIED DRUG; VALPROIC ACID;

ADD ON THERAPY; BEDTIME DOSAGE; COMORBIDITY; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DRIVING ABILITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; GLUCOSE INTOLERANCE; HUMAN; INSOMNIA; LEARNING DISORDER; LOW DRUG DOSE; MEMORY DISORDER; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NEUROPATHIC PAIN; OFF LABEL DRUG USE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POLYSOMNOGRAPHY; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIAPISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP QUALITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FATIGUE; HUMANS; HYPNOTICS AND SEDATIVES; OFF-LABEL USE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84870814425     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0302-y     Document Type: Review

References (73)

1. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep. 1999;22:371-5. (Pubitemid 29230580)
2. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep. 2004;27:1441-2. (Pubitemid 40041609)
3. Owens J, Rosen C, Mindell J, et al. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11:692-700.
4. Mindell J, Emslie G, Blumer L, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006;117:1223-32.
5. Poceta J. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7:632-8.
6. Rottach K, Schaner BM, Kirch M. Restless leg syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43:70-5.
7. Schweitzer P, et al. Drugs that disturb sleep and wakefulness. In: Kryger M, Roth T, Dement, editors. Principles and practice of sleep medicine. 5th ed. St Louis: Elsevier Saunders; 2012. p. 542.
8. Weber J, Siddiqui M, Wagstaff A. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010;24:713-20.
9. Kuntz R. Off-label prescribing of antidepressants and anxiolytics: an attorney's guide to psychoactive drugs. J Psychiatry Law. 1998;26:519-32. (Pubitemid 29194260)
10. Kramer S, McCall V. Off-label prescribing: 7 steps for safer, more effective treatment. Curr Psychiatry. 2006;5:15-28.
11. McCall W. Off-label use of prescription medications for insomnia: sedating antidepressants, antipsychotics, anxiolytics, and anticonvulsants. In: Sateia M, Buysse D, editors. Insomnia: diagnosis and treatment. London: Informa Healthcare; 2010. p. 397-409.
12. Dording C, Mischoulon D, Petersen T, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002;14:143-7. (Pubitemid 36172562)
13. Montgomery I, Oswald I, Morgan K, et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16:139-44. (Pubitemid 13031099)
14. Yamadera H, Nakamura S, Suzuki H, et al. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci. 1998;52:439-43. (Pubitemid 28412954)
15. Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry. 1990;51:18-22. (Pubitemid 20382326)
16. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469-76. (Pubitemid 40593575)
17. Haffmans PMJ. The effects of trazodone on sleep disturbances included by brofaromine. Eur Psychiatry. 1999;14:167-71. (Pubitemid 36187799)
18. Nierenberg A, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069-72. (Pubitemid 24208646)
19. Burns M, Hoskowitz H, Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. J Clin Psychiatry. 1986;47:252-4. (Pubitemid 16078413)
20. Warrington SJ, Ankier SI, Turner P. An evaluation of possible interactions between ethanol and trazodone or amitriptyline. Br J Clin Pharmacol. 1984;18:549-57. (Pubitemid 14009948)
21. Saletu-Zyhlarz G, Abu-Bakr M, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology. 2001;44:139-49. (Pubitemid 34701621)
22. James S, Mendelson W. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752-5.
23. Roth A, McCall W, Vaughn, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20:552-8.
24. Wichniak A, Wierzbicka A, Jernajczyk W. Patinets with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1671-6.
25. Sheehan D, Croft H, Gossen E, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry. 2009;6:20-33.
26. Calandre E, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a 2-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord. 2011;12:95.
27. Morillas-Arques P, Rodriguez-Lopez C, Molina-Barea R, et al. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:204.
28. Camargos E, Pandolfi M, Freitas M, et al. Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. Arq Neuropsiquiatr. 2011;69:44-9.
29. Stein M, Kurth M, Sharkey K, et al. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120:65-73.
30. Kupfer DJ, Spiker DG, Coble P, et al. Amitriptyline and EEG sleep in depressed patients: I. Drug effect Sleep. 1978;1:149-59.
31. Doerr J, Spiegelhalder K, Petzold F, et al. Impact of escitalopram on nocturnal sleep, day-time sleepiness, and performance compared to amitriptyline: a randomized, double-blind, placebo-controlled study in healthy male subjects. Pharmacopsychiatry. 2010;43:166-73.
32. Ware M, Fitzcharles M, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110:604-10.
33. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30:1555-61. (Pubitemid 350036981)
34. Krystal A, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433-42.
35. Krystal A, Durrence HH, Scharf M. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33:1553-61.
36. Lankford A, Rogowski R, Essink B, et al. Efficacy and safety of doxepin 6 mg in a 4-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med. 2012;13:133-8.
37. Ruigt GSF, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol. 1990;38:551-4. (Pubitemid 20206026)
38. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25:677-9. (Pubitemid 34977508)
39. Perez D, Loprinzi D, Barton DL. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004;2:50-6. (Pubitemid 39430230)
40. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005;66:436-43. (Pubitemid 40593571)
41. Shen J, Hossain N, Streiner D, et al. Excessive daytime sleepiness and fatigue in depressed patients and therapeutic response of a sedating antidepressant. J Affect Disord. 2011;134:421-6.
42. Shen J, Moller H, Wang X, et al. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry. 2009;70:370-7.
43. Dolev Z. Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-releasemelatonin add-on and monotherapy. Arch Womens Ment Health. 2011;14:269-73.
44. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology. 2004;174:421-9. (Pubitemid 39044301)
45. Wiegand M, Landry F, Bruckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196:337-8.
46. Nanda F, Singer C. Placebo-Controlled Trial of Quetiapine for Sleep Disturbance in Dementia and MCI. 16 ed. 2008;A126.
47. Cates M, Jackson C, Feldman J, et al. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45:251-4.
48. Dolder C, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm. 2010;25:676-9.
49. Tassniyom K, Paholpak S, Tassniyom S, et al. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010;93:729-34.
50. Golubchik P, Sever J, Weizman A. A low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011;34:216-9.
51. Stein D, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder: an analysis of pooled data from 3 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26:614-28.
52. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of 2 randomized, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127:19-30.
53. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002;43:1493-7. (Pubitemid 35429766)
54. Karam-Hage M, Brower K. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57:542-4. (Pubitemid 37247752)
55. Furieri F, Nakamura-Placios E. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691-700. (Pubitemid 350247498)
56. Arnold LM, Goldenberg D, Stanford S, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336-44. (Pubitemid 46608659)
57. Hahn K, Arendt G, Braun J, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004;251:1260-6. (Pubitemid 39517931)
58. Rice A, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain. 2001;94:215-24. (Pubitemid 33016615)
59. Backonja M. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1990;40(Suppl):S57-9.
60. Gordh T, Stubhaug A, Jenson T, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain. 2008;138:255-66.
61. Lo H, Yang C, Lo H, et al. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010;33:84-90.
62. Yurcheshen M, Guttuso TJ, McDermott M, et al. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh sleep quality index factor scoring model. J Womens Health. 2009;18:1355-60.
63. Myrick H, Malcolm R, Randall P. A double-blind trial of gabapentin vs lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582-8.
64. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28:187-93. (Pubitemid 40362644)
65. Arnold LM, Russell I, Diri E, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792-805.
66. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from 7 randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448-54.
67. Mease P, Russell I, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-14. (Pubitemid 351374429)
68. Siddall P, Cousins M, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67:1792-800. (Pubitemid 44900755)
69. Russell I, Crofford L, Leon T. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med. 2009;10:604-10.
70. Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011;38:2643-52.
71. Montgomery S, Herman B, Schweizer E, et al. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol. 2009;24:214-22.
72. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20:1979-91. (Pubitemid 40179637)
73. Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7:397-406. (Pubitemid 44103494)